Isomorphic Labs, an AI-driven drug discovery company, has successfully raised $2.1 billion in a Series B funding round, primarily led by Thrive Capital and supported by Alphabet and Google’s GV. This significant investment aims to enhance its AI platform and therapeutic pipeline, further advancing its drug discovery capabilities.
Founded by Demis Hassabis of Google DeepMind in 2021, Isomorphic Labs is leveraging predictive and generative AI models to innovate drug discovery processes. Central to their efforts is the IsoDDE (Isomorphic Labs Drug Design Engine), which is designed to improve the prediction of molecular interactions, thereby streamlining the discovery of new treatments across various therapeutic areas. Additionally, the company has developed AlphaFold 3, which assists in predicting molecular structures and interactions.
The newly acquired funds will not only enhance the IsoDDE but also support the company’s clinical talent and therapeutic pipeline, with plans to initiate its first clinical trial by the end of 2026. Ruth Porat, of Alphabet and Google, expressed optimism about Isomorphic's progress, highlighting the potential of their technology to accelerate drug discovery and bring new interventions to market more swiftly.
This latest funding round follows a previous raise of $600 million last year, indicating robust investor confidence in Isomorphic's mission. The company is also expanding its collaborations with major pharmaceutical firms like Novartis and Eli Lilly, which are estimated to be worth $3 billion, further solidifying its position in the AI-driven drug discovery landscape.